P-53 protein and proteins from BCL-2 family in the heart of rat after adriamycin administration. Immunohistochemical evaluation

• Autorzy: Boratynski Z. , Pedrycz A.
• Języki publikacji: EN

Abstrakty

EN

Adriamycin (ADR) – the antineoplastic antibiotics has confirmed proapoptotic activity, mainly on neoplastic cells and young quick dividing cells. Cardiotoxicity of Adriamycin is limitating in antineoplastic therapy. The purpose of study was an evaluation of internal pathway of induction of signal to the apoptosis in myocardial cells of rat, which had administered Adriamycin. The sign of late cardiotoxicity after Adriamycin is coagulative necrosis. In present study was noticed also increased apoptosis of cells in rat heart, which was induced via mitochondrial pathway, with activation of p-53 protein and with BAX/Bcl-2 ratio > 1 – with prevalence of proapoptotic BAX protein.

Słowa kluczowe

EN

cardiotoxicity; immunohistochemistry; neoplastic cell; adriamycin; protein; p53 protein; Bcl-2 family; apoptosis; rat; antineoplastic drug; heart

• Wydawca: -
• Czasopismo: Electronic Journal of Polish Agricultural Universities. Series Veterinary Medicine
• Rocznik: 2006
• Tom: 09
• Numer: 2
• Opis fizyczny: http://www.ejpau.media.pl/volume9/issue2/art-11.html

Twórcy

autor

Boratynski Z.

• Agricultural University of Lublin, Akademicka 12, 20-934 Lublin, Poland

autor

Pedrycz A.

Bibliografia

• Asakura T., Sawai T., Hashidume Y., Yokoyama S., Ohkawa K.: Caspase-3 activation during apoptosis caused by glutathione-doxorubicin conjugate. Br J Cancer, 1999, 80: 711- 715.
• Carter SK.: Cancer chemotherapy: new developments and changing concepts. Drugs 1980, 20: 375-397.
• Castedo M., Hirsch T., Susin SA., Zamzami N., Marchetti p., Macho A., Kroemer G.: Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J immunol, 1996, 157: 512-521.
• Chibowski D., Siezieniewska Z., Kleinrok Z., Chmielewska B.: Morphological and ultrastructural indicators of early cardiotoxicity in rats after the administration of rubidomycin and its derivatives. Patol Pol 1984, 35: 453-479.
• Chmielewski M., Linke K., Zabel M., Szuber L.: Apoptosis in the liver. Gastroent. Pol, 2003, 10: 453-462.
• Czarnecki A.: Doxorubicin induced cardiomyopathy. Pol. Tyg. Lek., 1983, 438:471[in Polish].
• Domiński Z.: Apoptosis: a cell death during animal’s live. Kosmos, 1999, 48: 385-396 [in Polish].
• Drzewoski J.: Influence of Doxorubicin (adriamycin) on haemodynamic parameters in rabbits‘ heart and interaction with digoxin, propranolol, coenzyme Q10. Praca habilitacyjna AM ŁódŸ, 1986 [in Polish].
• Hsu YL., Kuo PL., Tzeng WS., Lin CC.: Chalcone inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis. Food Chem Toxicol, [abstr], art in press, 2005.
• Kleinrok Z., Chmielewska B., Kozicka M., Kolasa k., Chibowski D., Siezieniewska Z.: Comparison of some properties of rubidomycine and its four derivatives. Arch Immunol Ther Exp 1986, 34: 239-244.
• Kleinrok Z., Chmielewska B., Sawiniec Z., Chibowski D., Siezieniewska Z.: Comparison of subacute toxicity of rubidomycine and its four derivatives. Arch Immunol Ther Exp 1986, 34: 251-257.
• Lampidis TJ., Henderson IC., Israel M., Canellos GP.: Structural and functional effects of adriamycin on cardiac cells in vitro. Cancer Res 1980, 40: 3901-3909.
• Mettler FP., Young DM., Ward JM.: Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 1977, 37: 2705-2713.
• Oz E., Erbas D., Surucu HS., Duzgun E.: Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol Cell Biochem 2006, 282: 31-37.
• Rosenoff SH., Olson HM., Young DM., Bostick F., Young RC.: Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity. J Natl Cancer Inst 1975, 55: 191-194.
• Serafino A., Sinibaldi-Vallebona P., Lazzarino G., Tavazzi B., Di Pierro D., Rasi G., Ravagnan G.: Modifications of mitochondria in human tumor cells during anthracycline-induced apoptosis. Anticancer Res 2000, 20: 3383-3394.
• Sinha BK., Gregory JL.: Role of one-electron and two-electron reduction products of adriamycin and daunomycin in deoxyribonucleic acid binding. Biochem Pharmacol. 1981, 30: 2626-2629.
• Smith SC., Leung TN., To KF., Baker PN.: Apoptosis is a rare event in first-trimester placental tissue. Am J Obstet Gynecol 2000, 183: 697-699.
• Speth PA., Van Hoesel QG., Haanen C.: Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988, 15: 15-31.
• Taylor AL., Bulkley BH.: Acute adriamycin cardiotoxicity: morphologic alterations in isolated perfused rabbit heart. Lab Invest 1982, 47: 459-464.
• Unverferth DV., Yagorian RD., Leier CV., Balcerzak SP.: Doxorubicin cardiotoxicity. Cancer Treat Rev. 1982, 9: 149-164.
• Wilk J.: Heart damage after treatment of neoplasms with cytostatics. Pol Tyg Lek 1983, 38: 853-855.
• Wolter KG., Hsu YT., Smith CL., Nechushtan A., Xi XG., Youle RJ.: Movenment of BAX from the cytosol to mitochondria during apoptosis. J. Cell Biol., 1997, 139: 1281-1292.
• Zeidan Q., Strauss M., Porras N., Anselmi G.: Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection. 2002, 34: 315-321.
• Zeman K.: Role of neuthrophils in inflammation. Inflammation. Pathophysiology and clinic. Medpress. W-wa, 1998, 76-97.
• Zeman K., Kantorski J., Paleolog EM., Feldmann M., Tchorzewski H.: The role of receptors for tumour necrosis factor-alpha in the induction of human polymorphonuclear neutrophil chemiluminescence. Immunol Lett 1996, 53: 45-50.